Journal of Gastrointestinal Cancer最新文献

筛选
英文 中文
Histotripsy for Liver Malignancies: A Systematic Review of the Existing Literature. 肝脏恶性肿瘤的组织学检查:对现有文献的系统回顾。
IF 2.2
Journal of Gastrointestinal Cancer Pub Date : 2026-11-14 DOI: 10.1007/s12029-026-01632-6
Morgan E Roberts, Natalie M Bath
{"title":"Histotripsy for Liver Malignancies: A Systematic Review of the Existing Literature.","authors":"Morgan E Roberts, Natalie M Bath","doi":"10.1007/s12029-026-01632-6","DOIUrl":"10.1007/s12029-026-01632-6","url":null,"abstract":"<p><strong>Background: </strong>Histotripsy is an emerging noninvasive, nonthermal ablative therapy recently introduced for the treatment of hepatic malignancies. This systematic review evaluated the efficacy and safety of histotripsy for primary and secondary liver tumors.</p><p><strong>Methods: </strong>PubMed and Scopus were searched from inception through August 2026 in accordance with PRISMA guidelines. Search terms included combinations of subject headings and keywords such as \"histotripsy,\" \"hepatic,\" and \"metastases.\"</p><p><strong>Results: </strong>Ten clinical studies published between 2022 and 2026 met inclusion criteria. Study populations included hepatocellular carcinoma and metastases from colorectal, neuroendocrine, pancreatic, breast, and other malignancies. Technical success ranged from 68.8% to 100%, although definitions varied across studies. Early treatment efficacy and local control were generally high among successfully treated tumors, with several studies reporting rates exceeding 90%. Longer-term oncologic data were limited by heterogeneous imaging criteria, treatment intent, and patient populations. Major complications were uncommon, although vascular thrombosis and acute kidney injury emerged as potential safety concerns.</p><p><strong>Conclusions: </strong>Current evidence supports the technical feasibility and short-term efficacy of hepatic histotripsy. However, standardized outcome definitions, longer follow-up, and comparative studies are needed to establish its durability and role relative to existing liver-directed therapies.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"57 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13769680/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149407120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epstein-Barr Virus-Positive Gastric Cancer in the Immunotherapy Era: Diagnostic Standards, Biomarker Context, and the Limits of Treatment Selection. Epstein-Barr病毒阳性胃癌在免疫治疗时代:诊断标准、生物标志物背景和治疗选择的限制。
IF 2.2
Journal of Gastrointestinal Cancer Pub Date : 2026-11-13 DOI: 10.1007/s12029-026-01633-5
Tamotsu Sagawa, Masahiro Hirakawa, Hiroyuki Nagashima, Koshi Fujikawa
{"title":"Epstein-Barr Virus-Positive Gastric Cancer in the Immunotherapy Era: Diagnostic Standards, Biomarker Context, and the Limits of Treatment Selection.","authors":"Tamotsu Sagawa, Masahiro Hirakawa, Hiroyuki Nagashima, Koshi Fujikawa","doi":"10.1007/s12029-026-01633-5","DOIUrl":"https://doi.org/10.1007/s12029-026-01633-5","url":null,"abstract":"<p><strong>Background: </strong>Epstein-Barr virus-positive gastric cancer (EBVaGC) is an immunologically enriched molecular subtype characterized by extensive DNA hypermethylation, recurrent PIK3CA alterations, 9p24.1/JAK2/PD-L1/PD-L2 abnormalities, and a lymphocyte-rich microenvironment. Although early studies suggested exceptional sensitivity to immune checkpoint inhibitors (ICIs), subsequent clinical evidence has demonstrated heterogeneous responses.</p><p><strong>Methods: </strong>This narrative review synthesizes molecular, pathological, and clinical evidence concerning the diagnosis of EBVaGC, its immune microenvironment, and the predictive significance of EBV positivity for immunotherapy across disease stages.</p><p><strong>Results: </strong>EBER in situ hybridization within neoplastic epithelial cells remains the diagnostic standard. Clinical studies indicate that EBV positivity may enrich for ICI responsiveness, but primary resistance occurs. An exploratory CheckMate 649 analysis showed a directionally favorable overall-survival effect with nivolumab plus chemotherapy, while a first-line observational study suggested that benefit may be concentrated in tumors with higher PD-L1 combined positive scores. A 2026 phase II perioperative trial reported encouraging pathological responses but was small and uncontrolled. EBV positivity remains distinct from microsatellite instability-high status in its level of clinical validation.</p><p><strong>Conclusions: </strong>EBV positivity provides important biological and diagnostic information but should not currently serve as a standalone determinant of ICI use. Treatment selection should integrate established biomarkers, disease stage, and approved indications. Prospective validation of composite biomarkers is required.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"57 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149407119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Postoperative Management After Curative-Intent Resection of Colorectal Liver Metastases: A Critical Review of Recent Randomized Evidence. 有意治愈的结直肠肝转移瘤切除术后的术后处理:近期随机证据的重要回顾。
IF 2.2
Journal of Gastrointestinal Cancer Pub Date : 2026-11-13 DOI: 10.1007/s12029-026-01638-0
Tamotsu Sagawa, Masahiro Hirakawa, Hiroyuki Nagashima, Koshi Fujikawa
{"title":"Postoperative Management After Curative-Intent Resection of Colorectal Liver Metastases: A Critical Review of Recent Randomized Evidence.","authors":"Tamotsu Sagawa, Masahiro Hirakawa, Hiroyuki Nagashima, Koshi Fujikawa","doi":"10.1007/s12029-026-01638-0","DOIUrl":"https://doi.org/10.1007/s12029-026-01638-0","url":null,"abstract":"<p><strong>Background: </strong>Postoperative management after curative-intent treatment of colorectal liver metastases (CRLM) remains controversial because improvements in recurrence-related outcomes have not consistently translated into longer overall survival (OS).</p><p><strong>Methods: </strong>This critical narrative review examines randomized evidence for systemic chemotherapy and hepatic arterial infusion (HAI), together with emerging evidence on circulating tumor DNA (ctDNA). Trial-based findings, prognostic associations, and unvalidated treatment-effect hypotheses were critically distinguished.</p><p><strong>Results: </strong>Postoperative fluoropyrimidine- or oxaliplatin-based treatment can delay recurrence in some settings, but a durable OS benefit has not been consistently demonstrated. Contemporary HAI trials differ in patient selection, regional drugs, systemic therapy, and endpoints. PACHA-01 reported improved hepatic recurrence-free survival in a selected population, HARVEST was terminated early, and PUMP did not meet its primary endpoint. These findings neither establish routine HAI nor identify validated predictors of benefit. Postoperative ctDNA is strongly prognostic, but nonrandomized associations between adjuvant treatment and outcomes cannot establish the clinical utility of ctDNA-directed treatment allocation.</p><p><strong>Conclusions: </strong>A conceptual distinction between hepatic and systemic recurrence risk may support multidisciplinary deliberation and prospective trial design, but should not be used as a validated postoperative treatment-selection algorithm. Clinical decisions must also account for prior chemotherapy, postoperative recovery, toxicity, local treatment opportunities, institutional expertise, and patient preferences.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"57 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149407121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Postoperative Tumor-Informed Circulating Tumor DNA Status for Molecular Residual Disease Detection After Curative-Intent Resection of Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis. 胰腺导管腺癌术后肿瘤信息循环肿瘤DNA状态用于分子残留疾病检测:系统回顾和荟萃分析
IF 2.2
Journal of Gastrointestinal Cancer Pub Date : 2026-11-11 DOI: 10.1007/s12029-026-01629-1
Wajahat Mirza, Minhaj Rafi, Zubair Siddiqui, Malaika Mehboob, Mohammad Zian Khan, Khadeeja Khan, Muhammad Hashir Ishaq, Muhammad Shalikh, Masoud Altabawi, Abdullah Imtiaz, Rao Nouman Ali
{"title":"Postoperative Tumor-Informed Circulating Tumor DNA Status for Molecular Residual Disease Detection After Curative-Intent Resection of Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis.","authors":"Wajahat Mirza, Minhaj Rafi, Zubair Siddiqui, Malaika Mehboob, Mohammad Zian Khan, Khadeeja Khan, Muhammad Hashir Ishaq, Muhammad Shalikh, Masoud Altabawi, Abdullah Imtiaz, Rao Nouman Ali","doi":"10.1007/s12029-026-01629-1","DOIUrl":"10.1007/s12029-026-01629-1","url":null,"abstract":"<p><strong>Background: </strong>Pancreatic ductal adenocarcinoma (PDAC) frequently recurs after curative-intent resection, and conventional imaging and CA19-9 have limited sensitivity for detecting molecular residual disease (MRD). Tumor-informed circulating tumor DNA (ctDNA) may identify postoperative MRD, although the evidence is limited and heterogeneous.</p><p><strong>Methods: </strong>PubMed, Scopus, and Embase were searched from inception to July 9, 2026, following PRISMA 2020 guidelines. Eligible studies compared postoperative tumor-informed ctDNA-positive and ctDNA-negative patients after curative-intent treatment of pancreatic cancer for recurrence, survival, or lead time outcomes. Random-effects models were used to pool risk ratios (RRs) and hazard ratios (HRs). Heterogeneity, leave-one-out sensitivity, prespecified subgroups, ROBINS-I risk of bias, and GRADE certainty were assessed.</p><p><strong>Results: </strong>Five observational cohorts contributed 237 patients to the radiological recurrence comparison (84 ctDNA-positive and 153 ctDNA-negative). Postoperative ctDNA positivity was associated with increased radiological recurrence (RR 2.50; 95% CI 1.90-3.28; I²=20%), poorer disease-free survival (HR 8.11; 95% CI 3.51-18.73; I²=45%), and poorer overall survival (HR 5.15; 95% CI 2.67-9.94; I²=0%). The direction of the associations persisted in the reported leave-one-out assessments. Recurrence risk was higher in both the early-MRD/landmark and surveillance subgroups, with no statistically significant subgroup difference (P = 0.17).</p><p><strong>Conclusion: </strong>Postoperative tumor-informed ctDNA positivity was associated with an increased recurrence risk and inferior survival after curative-intent PDAC treatment, although a negative result did not reliably exclude residual disease. Prospective interventional studies are needed before ctDNA-guided surveillance or treatment modifications can be recommended for routine practice.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"57 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149394401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From ASCOLT to ALASCCA: A Practical Framework for Biomarker-Selected Adjuvant Aspirin in PI3K-Altered Colorectal Cancer. 从ASCOLT到ALASCCA:生物标志物选择的辅助阿司匹林治疗pi3k改变的结直肠癌的实用框架
IF 2.2
Journal of Gastrointestinal Cancer Pub Date : 2026-11-11 DOI: 10.1007/s12029-026-01637-1
Tamotsu Sagawa, Masahiro Hirakawa, Hiroyuki Nagashima, Koshi Fujikawa
{"title":"From ASCOLT to ALASCCA: A Practical Framework for Biomarker-Selected Adjuvant Aspirin in PI3K-Altered Colorectal Cancer.","authors":"Tamotsu Sagawa, Masahiro Hirakawa, Hiroyuki Nagashima, Koshi Fujikawa","doi":"10.1007/s12029-026-01637-1","DOIUrl":"10.1007/s12029-026-01637-1","url":null,"abstract":"<p><strong>Purpose: </strong>Postoperative aspirin has produced inconsistent results in molecularly unselected colorectal cancer, whereas ALASCCA supports a biomarker-selected strategy. We synthesize randomized, molecular, and mechanistic evidence and propose a cautious framework for clinical consideration.</p><p><strong>Methods: </strong>This clinically oriented narrative review searched PubMed/MEDLINE, ClinicalTrials.gov, jRCT, PROSPERO, ASCO and ESMO materials, and reference lists, with a final update on September 27, 2026. Randomized trials and prospective biomarker-selected evidence were prioritized.</p><p><strong>Results: </strong>ASCOLT and EPISODE-III/JCOG1503C did not meet their primary disease-free survival endpoints in unselected populations. SAKK 41/13 was underpowered but directionally supportive. In ALASCCA, aspirin 160 mg daily for 3 years reduced 3-year colorectal cancer recurrence in group A PIK3CA exon 9/20 hotspot tumors (7.7% vs. 14.1%; HR 0.49, 95% CI 0.24-0.98). Group B showed a favorable estimate (7.7% vs. 16.8%; HR 0.42, 95% CI 0.21-0.83) but was secondary and molecularly heterogeneous. Low-dose platelet COX-1/thromboxane inhibition is pharmacologically established; direct tumor-cell COX-2/PI3K effects remain less certain. Mature overall-survival data are lacking.</p><p><strong>Conclusion: </strong>Adjuvant aspirin should not be used universally after colorectal cancer resection. The strongest evidence applies to ALASCCA group A, while group B requires variant-level caution. Any use should preserve standard adjuvant therapy and incorporate bleeding risk, local guidance, and shared decision-making.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"57 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149394400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Incidence of Colorectal Cancer After Endoscopic Mucosal Resection: A Multicenter Electronic Health Record Cohort Study. 内镜粘膜切除术后结直肠癌的发病率:一项多中心电子健康记录队列研究
IF 2.2
Journal of Gastrointestinal Cancer Pub Date : 2026-11-07 DOI: 10.1007/s12029-026-01634-4
Mohamed H Eldesouki, Khaled Elfert, EzzElDien A Ibrahim, Mohammed Y Youssef, Aasma Shaukat, Shyam Thakkar
{"title":"Incidence of Colorectal Cancer After Endoscopic Mucosal Resection: A Multicenter Electronic Health Record Cohort Study.","authors":"Mohamed H Eldesouki, Khaled Elfert, EzzElDien A Ibrahim, Mohammed Y Youssef, Aasma Shaukat, Shyam Thakkar","doi":"10.1007/s12029-026-01634-4","DOIUrl":"10.1007/s12029-026-01634-4","url":null,"abstract":"<p><strong>Background: </strong>Endoscopic mucosal resection (EMR) is widely used for large and complex colorectal lesions and offers a less invasive alternative to surgery. Although adenoma recurrence after EMR has been described in procedural cohorts, real-world estimates of subsequent colorectal cancer (CRC) diagnoses after EMR across multicenter electronic health record (EHR) systems remain limited.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study using the TriNetX US Collaborative Network. Patients aged 40 years or older who underwent colonoscopy or sigmoidoscopy with EMR between January 1, 2016 and January 1, 2017 were included. Patients with Crohn's disease, ulcerative colitis, familial adenomatous polyposis, or CRC recorded on or before the index EMR date were excluded. The primary outcome was incident CRC, defined by ICD-10-CM codes C18, C19, and C20, assessed from January 1, 2018 through December 31, 2021 after a one-year washout period. Incidence rates are reported per 1,000 person-years with exact Poisson 95% confidence intervals (CIs). A sensitivity analysis was restricted to patients aged 50-75 years at index EMR.</p><p><strong>Results: </strong>Among 3,081 eligible patients, the mean age was 62.9 ± 8.89 years and 52% were female; 2,735 were at risk at the start of follow-up. Twenty-two incident CRC diagnoses occurred over 10,187.8 person-years, an incidence of 2.16 per 1,000 person-years (95% CI, 1.35-3.27). Each calendar year contained 10 or fewer events, so annual rates could not be estimated. Incidence was 2.54 (95% CI, 1.31-4.44) in males and 1.83 (95% CI, 0.88-3.36) in females. In the 50-75-year sensitivity cohort, 19 events occurred over 8,894.8 person-years (2.14 per 1,000 person-years; 95% CI, 1.29-3.34). During years 1-5 after index EMR, repeat EMR occurred in 119 patients (3.9%), colorectal surgery in 28 (0.9%), and subsequent colorectal polyp diagnoses in 1,321 (42.9%); no ESD procedures were identified.</p><p><strong>Conclusion: </strong>CRC diagnoses after EMR were uncommon in this multicenter EHR cohort, occurring at about 2 per 1,000 person-years. Event counts were too small to estimate annual trends or to compare incidence reliably across race and ethnicity groups. Studies linking EHR data to endoscopy and pathology reports are needed to identify preventable cancers after EMR.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"57 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13743588/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149370869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From Radical Resection to Organ Preservation in Locally Advanced Rectal Cancer: A Narrative Review of Risk-Adapted Management. 从根治性切除到局部晚期直肠癌的器官保存:风险适应管理的叙述性回顾。
IF 2.2
Journal of Gastrointestinal Cancer Pub Date : 2026-11-07 DOI: 10.1007/s12029-026-01623-7
Bulent Cetin, Irem Karaman, Dilek Erdem, Emir Fatih Kaya, Nilgun Ozbek Okumus
{"title":"From Radical Resection to Organ Preservation in Locally Advanced Rectal Cancer: A Narrative Review of Risk-Adapted Management.","authors":"Bulent Cetin, Irem Karaman, Dilek Erdem, Emir Fatih Kaya, Nilgun Ozbek Okumus","doi":"10.1007/s12029-026-01623-7","DOIUrl":"10.1007/s12029-026-01623-7","url":null,"abstract":"<p><strong>Purpose: </strong>To synthesise evidence informing risk-adapted treatment and organ preservation in locally advanced rectal cancer.</p><p><strong>Methods: </strong>This narrative review used targeted English-language searches of PubMed, Embase, and the Cochrane Library through 31 March 2026, supplemented by targeted source verification in September 2026.</p><p><strong>Results: </strong>Magnetic resonance imaging, mismatch repair status, recurrence risk, and patient preferences inform treatment selection. Total neoadjuvant therapy is established for higher-risk mismatch repair-proficient/microsatellite-stable disease. Chemoradiation followed by consolidation chemotherapy can improve organ-preservation probability compared with induction sequencing, without a demonstrated disease-free survival advantage. Selected lower-risk surgical candidates may receive chemotherapy with selective chemoradiation. Both short-course radiotherapy and long-course chemoradiation remain evidence-based options; the long-term locoregional failure signal in RAPIDO cannot be attributed to fractionation alone. Watch-and-wait requires multimodal confirmation of clinical complete response, intensive surveillance, and access to salvage surgery; oncological equivalence to immediate resection is unproven. Prospective dostarlimab data support non-operative management in selected mismatch repair-deficient rectal cancers, while long-term durability requires further evaluation.</p><p><strong>Conclusion: </strong>Management should integrate tumour anatomy, biology, treatment response, and patient priorities. Organ preservation requires careful selection and structured follow-up, with treatment intensity individualised rather than applied uniformly.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"57 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149370868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic Associations of AJCC Tumor Regression Grade After Neoadjuvant Therapy for Rectal Cancer: A Single-Center Retrospective Cohort Study. 直肠癌新辅助治疗后AJCC肿瘤消退等级与预后的关系:一项单中心回顾性队列研究。
IF 2.2
Journal of Gastrointestinal Cancer Pub Date : 2026-11-06 DOI: 10.1007/s12029-026-01627-3
Jianjun Chen, Zhulin Li, Yong Yang, Zhenjun Wang
{"title":"Prognostic Associations of AJCC Tumor Regression Grade After Neoadjuvant Therapy for Rectal Cancer: A Single-Center Retrospective Cohort Study.","authors":"Jianjun Chen, Zhulin Li, Yong Yang, Zhenjun Wang","doi":"10.1007/s12029-026-01627-3","DOIUrl":"10.1007/s12029-026-01627-3","url":null,"abstract":"<p><strong>Purpose: </strong>To assess associations of AJCC tumor regression grade (TRG) with recurrence, disease-free survival (DFS), and overall survival (OS) after neoadjuvant therapy and surgery for rectal cancer.</p><p><strong>Methods: </strong>This retrospective cohort included 216 patients operated on during 2014-2023. Favorable regression comprised TRG 0-1. The primary Cox model adjusted for pretreatment carcinoembryonic antigen, Charlson Comorbidity Index, and neoadjuvant chemotherapy class; a sensitivity model added ypTNM stage. Time-dependent adjuvant-treatment, competing-risk, proportional-hazards, and incremental-value analyses were performed.</p><p><strong>Results: </strong>Favorable and poor regression occurred in 106 and 110 patients. There were 49 recurrences, 61 DFS events, and 26 deaths. Crude recurrence was lower with favorable regression (16.0% versus 29.1%; P = 0.022). Favorable TRG was associated with DFS in the primary model (hazard ratio [HR] 0.501, 95% confidence interval [CI] 0.291-0.863), but not after ypTNM adjustment (HR 0.633, 95% CI 0.358-1.120). Corresponding OS HRs were 0.232 (95% CI 0.086-0.626) and 0.203 (95% CI 0.071-0.584). Optimism-corrected C-index increases after adding TRG were 0.007 (95% CI - 0.013-0.043) for DFS and 0.048 (95% CI - 0.025-0.128) for OS.</p><p><strong>Conclusion: </strong>Favorable TRG was associated with lower crude recurrence and better survival before postoperative-stage adjustment. The DFS association attenuated after stage adjustment, while the OS association persisted in exploratory analyses. Limited deaths, non-proportional hazards, and uncertain incremental performance preclude definitive independent prognostic claims.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"57 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149357476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Postoperative ctDNA in Resectable Esophageal Squamous Cell Carcinoma: From Molecular Residual Disease Detection Toward Risk-Adapted Adjuvant Therapy and Surveillance. 可切除食管鳞状细胞癌的术后ctDNA:从分子残留疾病检测到适应风险的辅助治疗和监测。
IF 2.2
Journal of Gastrointestinal Cancer Pub Date : 2026-11-06 DOI: 10.1007/s12029-026-01635-3
Tamotsu Sagawa, Masahiro Hirakawa, Hiroyuki Nagashima, Koshi Fujikawa
{"title":"Postoperative ctDNA in Resectable Esophageal Squamous Cell Carcinoma: From Molecular Residual Disease Detection Toward Risk-Adapted Adjuvant Therapy and Surveillance.","authors":"Tamotsu Sagawa, Masahiro Hirakawa, Hiroyuki Nagashima, Koshi Fujikawa","doi":"10.1007/s12029-026-01635-3","DOIUrl":"10.1007/s12029-026-01635-3","url":null,"abstract":"<p><strong>Background: </strong>Postoperative circulating tumor DNA (ctDNA) is emerging as a marker of molecular residual disease (MRD) after curative-intent treatment for esophageal squamous cell carcinoma (ESCC). This review evaluates its ability to refine recurrence-risk assessment beyond pathological response and its potential role in guiding adjuvant therapy and surveillance.</p><p><strong>Methods: </strong>A structured narrative review of studies evaluating perioperative and postoperative ctDNA in resectable ESCC was conducted using PubMed/MEDLINE through August 17, 2026, supplemented by citation tracking and clinical trial registry searches. Evidence was synthesized across treatment pathways, assay platforms, and postoperative management settings.</p><p><strong>Results: </strong>Across ESCC cohorts using digital PCR, fixed next-generation sequencing panels, and personalized tumor-informed assays, postoperative ctDNA positivity consistently identifies patients at increased risk of recurrence, although estimates remain imprecise in small cohorts. Serial testing can detect molecular relapse months before radiographic recurrence. Integrated pathology-MRD models demonstrate additional risk stratification within both pathological complete response and non-completeresponse groups. Observational findings suggest, but do not establish, that MRD-positive patients may derive greater benefit from adjuvant immunotherapy. Conversely, MRD negativity alone does not justify omission of indicated adjuvant treatment.</p><p><strong>Conclusions: </strong>Postoperative ctDNA provides complementary molecular risk information beyond conventional pathology in resectable ESCC. However, prospective MRD-guided trials are required before postoperative treatment or surveillance strategies can be routinely modified on the basis of ctDNA results alone.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"57 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149357475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Artificial Intelligence in Gallbladder Carcinoma: A Review of Research Studies and Clinical Evidence. 人工智能在胆囊癌中的应用:研究综述和临床证据。
IF 2.2
Journal of Gastrointestinal Cancer Pub Date : 2026-11-05 DOI: 10.1007/s12029-026-01625-5
Amirhosein Naseri, Mohammad Hossein Antikchi, Toloo Zavol-Deylami, Abolhasan Alijanpour, Alireza Negahi, Mehdi Khosravi-Mashizi, Hossein Najdsepas, Amirhossein Rahmani, Seyed Alireza Dastgheib, Hossein Neamatzadeh
{"title":"Artificial Intelligence in Gallbladder Carcinoma: A Review of Research Studies and Clinical Evidence.","authors":"Amirhosein Naseri, Mohammad Hossein Antikchi, Toloo Zavol-Deylami, Abolhasan Alijanpour, Alireza Negahi, Mehdi Khosravi-Mashizi, Hossein Najdsepas, Amirhossein Rahmani, Seyed Alireza Dastgheib, Hossein Neamatzadeh","doi":"10.1007/s12029-026-01625-5","DOIUrl":"10.1007/s12029-026-01625-5","url":null,"abstract":"<p><strong>Background: </strong>Gallbladder carcinoma (GBC) is the most common biliary tract malignancy and is usually diagnosed at an advanced stage. Artificial intelligence (AI), including radiomics, machine learning (ML) and deep learning (DL), is increasingly applied to its diagnosis, surgical management and prognostication, but how far the reported performance can be trusted is unclear.</p><p><strong>Methods: </strong>PubMed/MEDLINE, Embase, Web of Science, the Cochrane Library and Google Scholar were searched to 5 May 2026 using database-specific search strategies. Each primary prediction-model study was characterized separately by design, number of centers and validation type (internal, temporal or external).</p><p><strong>Results: </strong>Of 31 primary AI studies in GBC, 29 were retrospective, 22 were single-center and 24 reported internal validation only. In independent test or external cohorts, DL and ML models discriminated benign from malignant gallbladder lesions with areas under the curve (AUCs) of approximately 0.80-0.89; a multicenter model distinguishing xanthogranulomatous cholecystitis from GBC achieved an external AUC of 0.88, and automated computed tomography (CT) segmentation an external Dice score of 0.76. The best recurrence model achieved an AUC of 0.76 on internal (random-split) validation; none of the reviewed prognostic models reported a quantified external-validation estimate. Intraoperative AI is technically feasible but has no outcome data, and federated learning has been tested only in simulation.</p><p><strong>Conclusion: </strong>AI could plausibly assist several steps of GBC care, but the evidence is dominated by retrospective, single-center, internally validated studies from Asia, and metrics from different studies are not directly comparable. Prospective multicenter external validation, shared annotated datasets and standardized reporting are required before clinical adoption.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"57 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149342449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书